FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 370 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Pembrolizumab Does Not Prolong Overall Survival Compared to Chemotherapy in Platinum-Pretreated... September 20, 2021 Nivolumab vs Sorafenib in First-Line Treatment of Advanced Hepatocellular Carcinoma July 1, 2020 How longer waiting times are impacting teens and young adults April 27, 2023 Deaths from Metastatic Melanoma Drop Substantially in the United States April 21, 2020 Load more HOT NEWS Oncotype DX Breast Cancer Test May Be Less Accurate for Black... FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic... Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated,... How MRI add-ons could accelerate the development of new treatments
